Intellia to present Phase 3 HAELO data at EAACI 2026 congress

June 1, 2026 7:30 AM

Intellia Therapeutics Inc. (NASDAQ: NTLA) will present data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found